
Opinion|Videos|March 12, 2026
ASCO GU recap: Sam Chang, MD, on KEYNOTE-B15, SWOG S1602
Author(s)Sam S. Chang, MD, MBA
Fact checked by: Hannah Clarke
Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.
Advertisement
Advertisement
In the following video, Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer. Chang highlighted data in both non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), emphasizing findings that may directly influence clinical decision-making.
Related to this article

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement

